Annex to the Certificate of Accreditation No. M-032 dated 10.02.2026.

The Annex is an integral part of the Certificate of Accreditation

Scope of Accreditation

Accredited body: Medirex s. r. o.
Prostredná 13/49, 900 21 Svätý Jur

Organizational unit and workplace performing the activity of the Accredited Body:
Western Slovakia, Central Laboratory Bratislava, Galvaniho 17/C, 821 04 Bratislava
Western Slovakia, Central Laboratory Nitra, Novozámocká 67, 949 05 Nitra
Eastern Slovakia, Central Laboratory Košice, Magnezitárska 2/C, 040 13 Košice
Identification number of the accredited body: 407/M-032

Laboratory with fixed scope

Item	Object of examination		Established method		Other specifications (equipment, workplace etc.)
	Biological material/ matrix	Analyte / Parameter	Principe	Identification of method	
1.1	serum	Alanine Aminotransferase (ALT)	photometry	ALT, Lachema (SOP-M 1.1)	Advia 2400, Advia XPT *BA/KE*
1.2		Albumin (ALB)		Albumin, Siemens (SOP-M 1.2)	Advia 2400, Advia XPT *BA/KE*
1.3		Alkaline Phosphatase (ALP)		ALP, Lachema (SOP-M 1.3)	Advia 2400, Advia XPT *BA/KE*
1.4		α-Amylase (AMS)		AMS, Lachema (SOP-M 1.4)	Advia 2400, Advia XPT *BA/KE*
1.5		Aspartate Aminotransferase (AST)		AST, Lachema (SOP-M 1.5)	Advia 2400, Advia XPT *BA/KE*
1.6		Bilirubin Total (BILT)		BILT, Lachema (SOP-M 1.6)	Advia 2400, Advia XPT *BA/KE*
1.7		Total Protein (TP)		TP, Siemens (SOP-M 1.7)	Advia 2400, Advia XPT *BA/KE*
1.8		γ-Glutamyl-transferase (GGT)		GMT, Lachema (SOP-M 1.8)	Advia 2400, Advia XPT *BA/KE*
1.9		Cholesterol Total (CHOL)		CHOL, Lachema (SOP-M 1.9)	Advia 2400, Advia XPT *BA/KE*
1.10		Creatine Kinase (CK)		CK, Lachema (SOP-M 1.10)	Advia 2400, Advia XPT *BA/KE*
1.11		Lactate Dehydrogenase (LDH)		LDH, Lachema (SOP-M 1.11)	Advia 2400, Advia XPT *BA/KE*
1.12		Triacylglycerols (TAG)		TG, Lachema (SOP-M 1.12)	Advia 2400, Advia XPT *BA/KE*
1.13		Iron (Fe)		IRON_2, Siemens (SOP-M 1.13)	Advia 2400, Advia XPT *BA/KE*
1.14	serum, urine	Phosphorus (P)		IP, Siemens (SOP-M 1.14)	Advia 2400, Advia XPT *BA/KE*
1.15		Glucose (GLU)		GLU, Lachema (SOP-M 1.15)	Advia 2400, Advia XPT *BA/KE*
1.16		Magnesium (Mg)		MG, Siemens (SOP-M 1.16)	Advia 2400, Advia XPT *BA/KE*
1.17		Creatinine (CREA)		Creatinine, Dialab (SOP-M 1.17)	Advia 2400, Advia XPT *BA/KE*
1.18		Uric Acid (UA)		UA, Lachema (SOP-M 1.18)	Advia 2400, Advia XPT *BA/KE*
1.19		Urea (UREA)		UREA, Lachema (SOP-M 1.19)	Advia 2400, Advia XPT *BA/KE*
1.20		Calcium (Ca)		CA, Siemens (SOP-M 1.20)	Advia 2400, Advia XPT *BA/KE*

Annex to the Certificate of Accreditation No. M-032 dated 10.02.2026.

The Annex is an integral part of the Certificate of Accreditation

Item	Object of examination		Established method		Other specifications (equipment, workplace etc.)
	Biological material/ matrix	Analyte / Parameter	Principe	Identification of method	
1.21	serum, urine	Chloride (Cl)	potentiometry	Chloride, Siemens (SOP-M 1.21)	Advia 2400, Advia XPT *BA/KE*
1.22		Potassium (K)		Potassium, Siemens (SOP-M 1.22)	Advia 2400, Advia XPT *BA/KE*
1.23		Sodium (Na)		Sodium, Siemens (SOP-M 1.23)	Advia 2400, Advia XPT *BA/KE*
1.24	serum	C-Reactive Protein (CRP)	immunoturbidimetry	CRP, DiaSys (SOP-M 1.24)	Advia 2400, Advia XPT *BA/KE*
1.25		Immunoglobulin A (IgA)		IgA, DiaSys (SOP-M 1.25)	Advia 2400, Advia XPT *BA/KE*
1.26		Immunoglobulin G (IgG)		IgG, DiaSys (SOP-M 1.26)	Advia 2400, Advia XPT *BA/KE*
1.27		Immunoglobulin M (IgM)		IgM, DiaSys (SOP-M 1.27)	Advia 2400, Advia XPT *BA/KE*
1.28		Transferrin (Trf)		TRF, Siemens (SOP-M 1.28)	Advia 2400, Advia XPT *BA/KE*
2.1		α-Fetoprotein (AFP)	electrochemi – luminiscence immunoassay	AFP cobas, Roche (SOP-M 2.1)	cobas 8000 *BA/KE*
2.2		Procollagen-type 1 N-terminal propeptide (P1NP)		total P1NP cobas, Roche (SOP-M 2.2)	cobas 8000 *BA/KE*
2.3		β – Isomerized C – terminal telopeptides of type I collagen (CTx)		β - CrossLaps/ serum cobas, Roche (SOP-M 2.3)	cobas 8000 *BA/KE*
2.4		Cancer antigen 125 (CA-125)		CA 125 II cobas, Roche (SOP-M 2.4)	cobas 8000 *BA/KE*
2.5		17β-Estradiol (E2)		Estradiol III cobas, Roche (SOP-M 2.5)	cobas 8000 *BA/KE*
2.6		Follicle stimulating hormone (FSH)		FSH cobas, Roche (SOP-M 2.6)	cobas 8000 *BA/KE*
2.7		Choriogonado-tropin (hCG)		HCG+β cobas, Roche (SOP-M 2.7)	cobas 8000 / *BA/KE* cobas e411 / *KE*
2.8		Immunoglobulin E (IgE)	chemiluminiscence immunoassay	IgE Advia Centaur, Siemens (SOP-M 2.8)	Advia Centaur XPT / *BA/KE* Advia Centaur XP / *KE*
2.9		Carcinoembryo-nic antigen (CEA)		CEA Advia Centaur, Siemens (SOP-M 2.9)	Advia Centaur XPT / *BA/KE* Advia Centaur XP / *KE*
2.10		Luteinizing hormone (LH)	electrochemi – luminiscence immunoassay	LH cobas, Roche (SOP-M 2.10)	cobas 8000 *BA/KE*
2.11		N-terminal pro-B-type natriuretic peptide (NT-proBNP)		proBNP II cobas, Roche (SOP-M 2.11)	cobas 8000 / *BA/KE* cobas e411 / *KE*
2.12		Pregnancy associated plasma protein A (PAPP-A)		PAPP-A cobas, Roche (SOP-M 2.12)	cobas 8000 / *BA/KE* cobas e411 / *KE*

Annex to the Certificate of Accreditation No. M-032 dated 10.02.2026.

The Annex is an integral part of the Certificate of Accreditation

Item	Object of examination		Established method		Other specifications (equipment, workplace etc.)
	Biological material/ matrix	Analyte / Parameter	Principe	Identification of method	
2.13	serum	Parathyroid hormone intact (PTH)	electrochemi – luminiscence immunoassay	PTH cobas, Roche (SOP-M 2.13)	cobas 8000 *BA/KE*
2.14		Progesterone (PROG)		Progesterone III cobas, Roche (SOP-M 2.14)	cobas 8000 *BA/KE*
2.15		Testosterone (TST)		Testosterone II cobas, Roche (SOP-M 2.15)	cobas 8000 *BA/KE*
2.16		Troponin T cardiac – high sensitive (hs cTnT)		Troponin T hs, STAT cobas, Roche (SOP-M 2.16)	cobas 8000 / *BA/KE* cobas e411 / *KE*
2.17		Ferritin (FER)	chemiluminiscence immunoassay	FER Advia Centaur, Siemens (SOP-M 2.17)	Advia Centaur XPT / *BA/KE* Advia Centaur XP / *KE*
2.18		Prostate-specific antigen (tPSA)		PSA Advia Centaur, Siemens (SOP-M 2.18)	Advia Centaur XPT / *BA/KE* Advia Centaur XP / *KE*
2.19		Prostate-specific antigen free (fPSA)		fPSA Advia Centaur, Siemens (SOP-M 2.19)	Advia Centaur XPT *BA/KE*
2.20		Thyrotropin (TSH)	electrochemi – luminiscence immunoassay	TSH cobas, Roche (SOP-M 2.20)	cobas 8000 *BA/KE*
2.21		Triiodothyronine free (fT3)		FT3 III cobas, Roche (SOP-M 2.21)	cobas 8000 *BA/KE*
2.22		Thyroxine free (fT4)		FT4 IV cobas, Roche (SOP-M 2.22)	cobas 8000 *BA/KE*
3.1		Protein electrophoresis (ELFO)	agarose gel electrophoresis	Hydragel 54 β1-β2, Sebia (SOP-M 3.1)	Hydrasys *BA/KE*
3.2	serum, urine	Monoclonal proteins (IF)	agarose gel electrophoresis and immuno-fixation	Hydragel 4 IF, Hydragel 4 Urine Profil, Sebia (SOP-M 3.2)	Hydrasys qualitative method *BA/KE*
3.3	peripheral blood	Glycated haemoglobin A1c (HbA1c)	HPLC	D-100, BioRad (SOP-M 3.3)	BioRad D-100 ionex HPLC method *BA/KE/NR*
4.1	peripheral blood	*Blood cell count with differential:*		BC-6800, BC-6200, BC-6000 Auto Hematology Analyzer, Mindray (SOP-M 4.1)	Mindray BC-6800 / *BA* Mindray BC-6200 / *KE/NR* Mindray BC-6000 / *BA/KE/NR*
		Hemoglobin (HGB)	photometry		
		Erythrocytes (RBC)	electrical impedance		
		Platelets (PLT)			
		Leukocytes (WBC)	flow cytometry		
		Neutrophils granulocytes (NEU)			
		Lymphocytes (LYM)			
		Monocytes (MONO)			
		Eosinophils granulocytes (EOS)			
		Basophils granulocytes (BASO)			

Annex to the Certificate of Accreditation No. M-032 dated 10.02.2026.

The Annex is an integral part of the Certificate of Accreditation

Item	Object of examination		Established method		Other specifications (equipment, workplace etc.)
	Biological material/ matrix	Analyte / Parameter	Principe	Identification of method	
4.2	plasma	Prothrombin time (PT)	coagulation assay	Thromborel S, Siemens (SOP-M 4.2)	Sysmex CS-5100 / *BA/KE* Sysmex CS-2500 / *KE/NR*
4.3		Thrombin time (TT)		Thromboclotin, Siemens (SOP-M 4.3)	Sysmex CS-5100 / *BA/KE* Sysmex CS-2500 / *KE/NR*
4.4		Fibrinogen (FBG)		Dade Thrombin Reagent, Siemens (SOP-M 4.4)	Sysmex CS-5100 / *BA/KE* Sysmex CS-2500 / *KE/NR*
4.5		Antithrombin III (AT III)	chromogenic assay	Berichrom Antithrombin III, Siemens (SOP-M 4.5)	Sysmex CS-5100 / *BA/KE* Sysmex CS-2500 / *KE*
4.6		D-dimer	immuno-turbidimetric assay	INNOVANCE D-Dimer, Siemens (SOP-M 4.6)	Sysmex CS-5100 / *BA/KE* Sysmex CS-2500 / *KE/NR*
5.1	peripheral blood	CD3+ CD3+CD4+ CD3+CD8+ NK cells B lymphocytes	flow cytometry	Navios Flow Cytometer, Monoclonal Antibodies, Beckman Coulter (SOP-M 5.1)	Navios, Navios EX / *BA/KE* Navios EX / *NR*
5.2	serum	Specific IgE	fluorescence immunoassay	ImmunoCAP 250, ImmunoCAP 1000, Phadia, Specific IgE (SOP-M 5.2)	ImmunoCAP 1000 / *BA* ImmunoCAP 250 / *KE* investigated allergens according to the manufacturer's offer of the mentioned measuring systems
6.1	peripheral blood, bone marrow	Fusion genes (BCR-ABL)	Real Time PCR	Reference 6.1 (SOP-M 6.1)	*BA/KE*
6.2	peripheral blood, bone marrow	V617F mutation of JAK2 gene	Real Time PCR	Reference 6.2 (SOP-M 6.2)	qualitative method *BA/KE*
6.3	peripheral blood, bone marrow, amniotic fluid	Molecular - cytogenetic analysis	FISH fluorescent in situ hybridization	Reference 6.3 (SOP-M 6.3)	qualitative method *BA*
6.4	peripheral blood	Karyotyping of chromosomes	Cytogenetic analysis of chromosomes after 72 hours peripheral blood cultivation	Reference 6.4 (SOP-M 6.4)	qualitative method *BA*
6.5	amniotic fluid	Chromosome aneuploidy 13,18,21,X and Y	PCR/fluorescent PCR	Reference 6.5 (SOP-M 6.5)	qualitative method *BA*
7.1	serum, plasma	Hepatitis B virus surface antigen (HBsAg)	electrochemi – luminiscence immunoassay	HBsAg II cobas, Roche (SOP-M 7.1)	cobas 8000 qualitative method *BA/KE*
7.2		Hepatitis B virus surface antibodies (anti-HBs)		Anti-HBs II cobas, Roche (SOP-M 7.2)	cobas 8000 *BA*

Annex to the Certificate of Accreditation No. M-032 dated 10.02.2026.

The Annex is an integral part of the Certificate of Accreditation

Item	Object of examination		Established method		Other specifications (equipment, workplace etc.)
	Biological material/ matrix	Analyte / Parameter	Principe	Identification of method	
7.3	serum, plasma	Hepatitis B virus core IgM antibodies (anti-HBc IgM)	electrochemi – luminiscence immunoassay	Anti-HBc IgM cobas, Roche (SOP-M 7.3)	cobas 8000 qualitative method *BA*
7.4		Hepatitis B virus core antibodies (anti-HBc total)		Anti-HBc total cobas, Roche (SOP-M 7.4)	cobas 8000 qualitative method *BA*
7.5		Hepatitis B virus e antigen (HBeAg)		HBeAg cobas, Roche (SOP-M 7.5)	cobas 8000 qualitative method *BA*
7.6		Hepatitis B virus e antibodies (anti-HBe)		Anti-HBe cobas, Roche (SOP-M 7.6)	cobas 8000 qualitative method *BA*
7.7		Hepatitis C virus antibodies (anti-HCV)		Anti-HCV II cobas, Roche (SOP-M 7.7)	cobas 8000 qualitative method *BA/KE*
7.8		Human immunodeficiency virus antigen and antibodies (HIV Ag/Ab)		HIV Combi PT, HIV duo cobas, Roche (SOP-M 7.8)	cobas 8000 qualitative method *BA/KE*
7.9		Hepatitis B virus DNA (HBV DNA)	Real Time PCR	HBV cobas, Roche (SOP-M 7.9)	cobas 6800 *BA*
7.10		Hepatitis C virus RNA (HCV RNA)		HCV cobas, Roche (SOP-M 7.10)	cobas 6800 *BA*
7.11	swabs, urine	DNA *Chlamydia trachomatis*		CT/NG cobas, Roche (SOP-M 7.11)	cobas 6800 qualitative method *BA*
7.12		DNA *Neisseria gonorrhoeae*		CT/NG cobas, Roche (SOP-M 7.12)	cobas 6800 qualitative method *BA*
8.1	blood culture	The presence of diagnostically significant microorganisms	cultivation	Reference 8.1 (SOP-M 8.1)	qualitative method *BA/KE/NR*
8.2	body fluid cultures (excluding blood, cerebrospinal fluid and urine)	The presence of diagnostically significant microorganisms		Reference 8.2 (SOP-M 8.2)	qualitative method *BA/KE/NR*
8.3	catheter tip cultures	The presence of diagnostically significant microorganisms		Reference 8.3 (SOP-M 8.3)	qualitative method *BA/KE*
8.4	cerebrospinal fluid	The presence of diagnostically significant microorganisms		Reference 8.4 (SOP-M 8.4)	qualitative method *BA/KE*

Annex to the Certificate of Accreditation No. M-032 dated 10.02.2026.

The Annex is an integral part of the Certificate of Accreditation

Item	Object of examination		Established method		Other specifications (equipment, workplace etc.)
	Biological material/ matrix	Analyte / Parameter	Principe	Identification of method	
8.5	fecal and other gastrointesti-nal specimens	The presence of diagnostically significant microorganisms	cultivation	Reference 8.5 (SOP-M 8.5)	qualitative method *BA/KE/NR*
8.6	specimens from genital tract	The presence of diagnostically significant microorganisms		Reference 8.6 (SOP-M 8.6)	qualitative method *BA/KE/NR*
8.7	human biological material (wound, ocular and otitis cultures)	The presence of diagnostically significant microorganisms		Reference 8.7 (SOP-M 8.7)	qualitative method *BA/KE/NR*
8.8	specimens from respiratory tract	The presence of diagnostically significant microorganisms		Reference 8.8 (SOP-M 8.8)	qualitative method *BA/KE/NR*
8.9	urine	The presence of diagnostically significant microorganisms		Reference 8.9 (SOP-M 8.9)	semiquantitative method *BA/KE/NR*
8.10	culture of microorga-nisms	Identification of microorganisms	mass spectrometry	Reference 8.10 (SOP-M 8.10)	Maldi Biotyper qualitative method *BA/KE*
8.11	human biological material and culture of microorga-nisms	The presence of microorganisms, cellular elements and identification of microorganisms	microscopic examination/staini ng procedures	Reference 8.11 (SOP-M 8.11)	qualitative method *BA/KE/NR*
8.12	culture of microorga-nisms	Identification of aerobic, fakultative anaerobic, microaerophilic and anaerobic bacteria	conventional biochemical tests, growth properties and antigen characteristic	Reference 8.12 (SOP-M 8.12)	qualitative method *BA/KE/NR*
8.13	culture of microorga-nisms	Growth and/or inhibition growth in the presence of antimicrobial agents	antimicrobial susceptibility testing (disc diffusion and microdilution method, MIC)	Reference 8.13 (SOP-M 8.13)	qualitative method *BA/KE/NR*
9.1	human biological material	The presence of microscopic fungi	cultivation	Reference 9.1 (SOP-M 9.1)	qualitative method *BA*
9.2		The presence of microscopic fungi and cell elements	microscopic examination	Reference 9.2 (SOP-M 9.2)	qualitative method *BA*
9.3	cultures of microscopic fungi	Micromorphological features of microscopic fungi		Reference 9.3 (SOP-M 9.3)	qualitative method *BA*

Annex to the Certificate of Accreditation No. M-032 dated 10.02.2026.

The Annex is an integral part of the Certificate of Accreditation

Item	Object of examination		Established method		Other specifications (equipment, workplace etc.)
	Biological material/ matrix	Analyte / Parameter	Principe	Identification of method	
9.4	cultures of microscopic fungi	Growth of microscopic fungi in presence specific substance and temperature	analysis of metabolic and growth features	Reference 9.4 (SOP-M 9.4)	qualitative method *BA*
9.5	cultures of microscopic fungi	Identification of microscopic fungi	mass spectrometry	Reference 9.5 (SOP-M č. 9.5)	Maldi Biotyper qualitative method *BA*
10.1	serum, plasma	IgM antibodies against *Toxoplasma gondii*	electrochemi – luminiscence immunoassay	Elecsys Toxo IgM cobas, Roche (SOP-M 10.1)	cobas 8000 qualitative method *BA*
10.2		IgG antibodies against *Toxoplasma gondii*		Elecsys Toxo IgG cobas, Roche (SOP-M 10.2)	cobas 8000 *BA*
10.3		Avidity of IgG antibodies against *Toxoplasma gondii*		Elecsys Toxo IgG Avidity cobas, Roche (SOP-M 10.3)	cobas 8000 qualitative method *BA*
10.4	stool	The presence of helminth eggs and protozoan cysts	microscopy	Reference 10.4 (SOP-M 10.4)	qualitative method *BA*
10.5	perianal tape test	The presence of *Enterobius vermicularis*		Reference 10.5 (SOP-M 10.5)	qualitative method *BA*

REMARKS:
SOP-M - Standard Operating Procedure for Method
BA - examination is done in Medirex, a.s. Western Slovakia, Central Laboratory Bratislava
KE - examination is done in Medirex, a.s. Eastern Slovakia, Central Laboratory Košice
NR - examination is done in Medirex, a.s. Western Slovakia, Central Laboratory Nitra

References:

6.1 FusionQuant Kits for Real-time Quantitative PCR Analysis of Fusion Gene Transcripts, Ipsogen, Cancer profiler, Instructions for use, 2009
https://www.qiagen.com/us/shop/detection-solutions/personalized-healthcare/ipsogen-bcr-abl 1-mbcr-is-mmr kits/#orderinginformation
Tempus TM Spin RNA Isolation Kit (kat. č. 4380204), (Life technologies)
https://tools.lifetechnologies.com/content/sfs/brochures/cms_057271.pdf
www.implen.co.uk/product.php5?id=100
Cross N. C., White H. E. et al. (2015): Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015 May; 29(5): 999-1003
Gabert J., Beillard E. et al. (2003): Standardization and quality control studies od ´real-time´ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe
Against Cancer program. Leukemia. 2003 Dec; 17(12):2318-57
6.2 "Ipsogen JAK2 MutaScreen Handbook": catalog no. 673013, QIAGEN GmbH, QIAGEN Strasse 1, 40724 Hilden, GERMANY, January 2013, www.qiagen.com
Magnesia 16, automated Nucleic Acid Extractor (Anatolia genexorks, www.anatoliagenetics.com)
6.3 ISCN (2016): An International System for Human Cytogenetic Nomenclature (2016).
McGowan-Jordan J., Simons A., Schmid M.; Karger, Basel 2016
http://www.metasystems-international.com
http://www.eurogentest.org/index.php?id=699
http://www.e-c-a.eu/files/downloads/Guidelines/NL31_Acquired_Guidelines.pdf
http://www.molecular.abbott/int/en/vysis-fish-chromosome-search
www.kreatech.com
www.zytovision.com
www.cytocell.com/probe

Annex to the Certificate of Accreditation No. M-032 dated 10.02.2026.

The Annex is an integral part of the Certificate of Accreditation

6.4. www.e-c-a.eu/en/
www.metasystems-international.com
www.acgs.uk.com
ISCN (2013): An International System for Human Genetic Nomenclature. Shaffer L. G., McGowan-Jordan J., Schmid M. (eds); S. Karger, Basel. 2013
Analyzing Chromosomes, Czepulkowski B.; BIOS Scientific Publishers Limitid, 2001
6.5 Návod k použití, Devyser Complete v2. CE-IVD, 7-A022-CZ, v2-2012
ISCN (2016): An International System for Human Cytogenetic Nomenclature (2016). McGowan-Jordan J., Simons A., Schmid M.; Karger, Basel 2016
8.1 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.4, 4
8.2 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.5, 4
8.3 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.6, 4
8.4 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.7, 4
8.5 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.8
8.6 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.9, 4
8.7 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.10, 3.13, 3.11.5
8.8 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.11
8.9 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.12
8.10 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 3, kap. 12.5
8.11 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.2
8.12 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.16, 3.17, 3.18, 4
8.13 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 2, kap. 5
8.14 Vyhláška MZ SR č. 553/2007
9.1 Jorgensen et al.: Manual of Clinical Microbiology, 11 Ed., 2015, Vol. 2., sekcia VI, kap. 114, 115, s. 1944-1964; Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 2, kap. 8.2, 8.4, 8.5
9.2 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 2., kap. 8.3, podkap. 8.3.1.1 - 8.3.1.9
Jorgensen et al.: Manual of Clinical Microbiology,11 Ed., 2015, Vol. 2, sekcia VI, kap. 116, str. 1965-1969
9.3 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 2., kap. 8.5, 8.6, 8.7, 8.9
9.4 Kurtzman et al.: Manual of Clinical Microbiology, 5 Ed., 2011, Vol. 1., kap. 7, s. 100-107
Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 2, kap. 8.7, 8.8, 8.9
9.5 BRUKER Daltonics, MBT Compass, Software and Manuals, Revision E1
BRUKER, MALDI Biotyper Laboratorní příručka
10.4 Ondriska, F., Boldiš, V., Garajová, M., Mrva, M.: Klinická parazitológia 1. vyd., 2016, kap. 10.1, 10.2, s. 227-229
10.5 Ondriska, F., Boldiš, V., Garajová, M., Mrva, M.: Klinická parazitológia 1. vyd., 2016, kap. 9.1.2, s. 221-222

***